Stine Emilie Weis-Banke

Stine Emilie Weis-Banke

Auto-generated profile, based on publicly available information

Stine Emilie Weis-Banke

National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JKJulie Westerlin Kjeldsen
Julie Westerlin Kjeldsen
CLCathrine Lund Lorentzen
Cathrine Lund Lorentzen
EMEvelina Martinenaite
Evelina Martinenaite
EEEva Ellebaek
Eva Ellebaek
Marco DoniaMarco Donia
Marco Donia
Inge MarieInge Marie
Inge Marie
Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study (https://clinicaltrials.gov/, NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7–90.5%) was reached, with 43% (CI, 27.4–60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4–69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of >93% of patients during vaccination. Vaccine-reactive T cells comprised CD4+ and CD8+ T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach.

1 September 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SWStine E. Weis-Banke
Stine E. Weis-Banke
MLMads Lerdrup
Mads Lerdrup
DKDaniela Kleine-Kohlbrecher
Daniela Kleine-Kohlbrecher
FMFaizaan Mohammad
Faizaan Mohammad
Simone SidoliSimone Sidoli
Simone Sidoli
PCPaul A.C. Cloos
Paul A.C. Cloos
The mutant protein FOXL2C134W is expressed in at least 95% of adult-type ovarian granulosa cell tumors (AGCT) and is considered to be a driver of oncogenesis in this disease. However, the molecular mechanism by which FOXL2C134W contributes to tumorigenesis is not known. Here, we show that mutant FOXL2C134W acquires the ability to bind SMAD4, forming a FOXL2C134W/SMAD4/SMAD2/3 complex that binds a novel hybrid DNA motif AGHCAHAA, unique to the FOXL2C134W mutant. This binding induced an enhancer-like chromatin state, leading to transcription of nearby genes, many of which are characteristic of epithelial-to-mesenchymal transition. FOXL2C134W also bound hybrid loci in primary AGCT. Ablation of SMAD4 or SMAD2/3 resulted in strong reduction of FOXL2C134W binding at hybrid sites and decreased expression of associated genes. Accordingly, inhibition of TGFβ mitigated the transcriptional effect of FOXL2C134W. Our results provide mechanistic insight into AGCT pathogenesis, identifying FOXL2C134W and its interaction with SMAD4 as potential therapeutic targets to this condition. Significance: FOXL2C134W hijacks SMAD4 and leads to the expression of genes involved in EMT, stemness, and oncogenesis in AGCT, making FOXL2C134W and the TGFβ pathway therapeutic targets in this condition. Graphical http://cancerres.aacrjournals.org/content/canres/80/17/3466/F1.large.jpg. Graphical Abstract

6 November 2019 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
EMEvelina Martinenaite
Evelina Martinenaite
SAShamaila Munir Ahmad
Shamaila Munir Ahmad
SBSimone Kloch Bendtsen
Simone Kloch Bendtsen
MJMia Aaboe Jørgensen
Mia Aaboe Jørgensen
SWStine Emilie Weis-Banke
Stine Emilie Weis-Banke
MAMads Hald Andersen
Mads Hald Andersen
L-arginine depletion by regulatory cells and cancer cells expressing arginase-1 (Arg-1) is a vital contributor to the immunosuppressive tumor microenvironment in patients with cancer. We have recently described the existence of pro-inflammatory effector T cells that recognize Arg-1. Hence, Arg-1-specific self-reactive T cells are a naturally occurring part of the memory T-cell repertoire of the human immune system. Here, we further characterize a highly immunogenic epitope from Arg-1. We describe frequent T-cell-based immune responses against this epitope in patients with cancer, as well as in healthy donors. Furthermore, we show that Arg-1-specific T cells expand in response to the TH2 cytokine interleukin (IL)-4 without any specific stimulation. Arg-1-specific memory TH1 cells that respond to increased IL-4 concentration may, therefore, drive the immune response back into the TH1 pathway. Arg-1-specific T cells thus appear to have an important function in immune regulation. Because Arg-1 plays an important role in the immunosuppressive microenvironment in most cancers, an immune modulatory vaccination approach can readily be employed to tilt the balance away from immune suppression in these settings.

1 January 2020 in OncoImmunology
Verified
Journal Article
Open access
SWStine Emilie Weis-Banke
Stine Emilie Weis-Banke
MHMie Linder Hübbe
Mie Linder Hübbe
MHMorten Holmström
Morten Holmström
MJMia Aaboe Jørgensen
Mia Aaboe Jørgensen
SBSimone Kloch Bendtsen
Simone Kloch Bendtsen
MAMads Hald Andersen
Mads Hald Andersen
One way that tumors evade immune destruction is through tumor and stromal cell expression of arginine-degrading enzyme arginase-2 (ARG2). Here we describe the existence of pro-inflammatory effector T-cells that recognize ARG2 and can directly target tumor and tumor-infiltrating cells. Using a library of 34 peptides covering the entire ARG2 sequence, we examined reactivity toward these peptides in peripheral blood mononuclear cells from cancer patients and healthy individuals. Interferon-γ ELISPOT revealed frequent immune responses against several of the peptides, indicating that ARG2–specific self-reactive T-cells are natural components of the human T-cell repertoire. Based on this, the most immunogenic ARG2 protein region was further characterized. By identifying conditions in the microenvironment that induce ARG2 expression in myeloid cells, we showed that ARG2-specific CD4T-cells isolated and expanded from a peripheral pool from a prostate cancer patient could recognize target cells in an ARG2-dependent manner. In the ‘cold’ in vivo tumor model Lewis lung carcinoma, we found that activation of ARG2-specific T-cells by vaccination significantly inhibited tumor growth. Immune-modulatory vaccines targeting ARG2 thus are a candidate strategy for cancer immunotherapy.

27 January 2022 in OncoImmunology
Verified
Journal Article
Open access
SBSimone Kloch Bendtsen
Simone Kloch Bendtsen
MPMaria Perez-Penco
Maria Perez-Penco
MHMie Linder Hübbe
Mie Linder Hübbe
EMEvelina Martinenaite
Evelina Martinenaite
MHMorten Holmström
Morten Holmström
MAMads Hald Andersen
Mads Hald Andersen
Galectin-3 (Gal3) can be expressed by many cells in the tumor microenvironment (TME), including cancer cells, cancer-associated fibroblasts, tumor-associated macrophages, and regulatory T cells (Tregs). In addition to immunosuppression, Gal3 expression has been connected to malignant cell transformation, tumor progression, and metastasis. In the present study, we found spontaneous T-cell responses against Gal3-derived peptides in PBMCs from both healthy donors and cancer patients. We isolated and expanded these Gal3-specific T cells in vitro and showed that they could directly recognize target cells that expressed Gal3. Finally, therapeutic vaccination with a long Gal3-derived peptide epitope, which induced the expansion of Gal3-specific CD8+ T cells in vivo, showed a significant tumor-growth delay in mice inoculated with EO771.LMB metastatic mammary tumor cells. This was associated with a significantly lower percentage of both Tregs and tumor-infiltrating Gal3+ cells in the non-myeloid CD45+CD11b− compartment and with an alteration of the T-cell memory populations in the spleens of Gal3-vaccinated mice. These results suggest that by activating Gal3-specific T cells by an immune-modulatory vaccination, we can target Gal3-producing cells in the TME, and thereby induce a more immune permissive TME. This indicates that Gal3 could be a novel target for therapeutic cancer vaccines.

8 March 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JKJulie Westerlin Kjeldsen
Julie Westerlin Kjeldsen
CLCathrine Lund Lorentzen
Cathrine Lund Lorentzen
EMEvelina Martinenaite
Evelina Martinenaite
EEEva Ellebaek
Eva Ellebaek
Marco DoniaMarco Donia
Marco Donia
Inge MarieInge Marie
Inge Marie